Mackie Thomas I, Tse Lisa L, de Ferranti Sarah D, Ryan Heather R, Leslie Laurel K
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
J Clin Lipidol. 2015 Jul-Aug;9(4):583-93.e1-3. doi: 10.1016/j.jacl.2015.04.008. Epub 2015 May 7.
Adolescents and young adults (AYAs) with familial hypercholesterolemia (FH) are at high risk for underdiagnosis and inadequate treatment. Yet, little is known about the factors that influence the medical decision making of AYAs with FH and their families.
This study explores how family medical history, family narratives of medical experiences, and AYA medical experiences together function as "experiential evidence" and influence screening and treatment decisions.
Twenty-four parents and AYAs affected by FH from a pediatric preventive cardiology practice responded to a survey and a semistructured qualitative interview. Transcribed interviews were analyzed using a modified grounded theory approach. Study design, instruments, and interpretation of results were informed by a 20-member stakeholder panel.
AYAs and parents reported extensive personal and family experiences with cholesterol and cardiovascular conditions and treatments, sometimes distinct from FH, which were used as evidence to inform their own perceptions of FH risk and treatment. This experiential evidence impacted perceptions of: (1) hereditary risk for FH diagnoses, (2) risk for future cardiovascular disease, (3) risks associated with treatments, and (4) capacity to comply with recommended treatments. Although experiences of family members initially informed screening and treatment decisions, the subsequent personal experiences of AYAs led to new experiential evidence that informed future decisions.
Family cardiovascular history related to and distinct from FH influenced screening and treatment decisions of AYAs and parents affected by FH. Additional clinical assessment of personal and family medical experiences may enhance understanding of the decision-making processes among AYAs and ultimately improve adherence to screening and treatment recommendations.
患有家族性高胆固醇血症(FH)的青少年和青年(AYA)面临诊断不足和治疗不充分的高风险。然而,对于影响患有FH的AYA及其家庭医疗决策的因素,我们知之甚少。
本研究探讨家族病史、家族医疗经历叙述以及AYA的医疗经历如何共同作为“经验证据”,影响筛查和治疗决策。
来自儿科预防心脏病学诊所的24名受FH影响的父母和AYA对一项调查和半结构化定性访谈做出了回应。使用改良的扎根理论方法对转录的访谈进行分析。研究设计、工具和结果解释由一个20名成员的利益相关者小组提供信息。
AYA和父母报告了在胆固醇、心血管疾病及治疗方面广泛的个人和家族经历,有时与FH不同,这些经历被用作证据来形成他们自己对FH风险和治疗的看法。这种经验证据影响了对以下方面的看法:(1)FH诊断的遗传风险,(2)未来心血管疾病的风险,(3)与治疗相关的风险,以及(4)遵守推荐治疗的能力。虽然家庭成员的经历最初影响了筛查和治疗决策,但AYA随后的个人经历产生了新的经验证据,为未来的决策提供了依据。
与FH相关及不同的家族心血管病史影响了受FH影响的AYA和父母的筛查和治疗决策。对个人和家族医疗经历进行额外的临床评估可能会增强对AYA决策过程的理解,并最终提高对筛查和治疗建议的依从性。